Jan Cosaert

2.2k citations

43 papers · 1.5k indexed · 2 hit papers · h-index 17

Impact in

Oncology top 2%
- Pancreatic and Hepatic Oncology Research
- Vascular Tumors and Angiosarcomas
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
Cancer Research top 5%
- Cancer Genomics and Diagnostics

Papers in

Oncology 26
- Colorectal Cancer Treatments and Studies 6
- Lung Cancer Research Studies 6
- Pancreatic and Hepatic Oncology Research 5
- Cancer Immunotherapy and Biomarkers 5
Pulmonary and Respiratory Medicine 22
- Lung Cancer Treatments and Mutations 9

Co-authors: Jaafar Bennouna Yves Humblet Chris Verslype Walter L. Vervenne Aijing Shang Malcolm J. Moore Eric Van Cutsem Jean‐Luc Van Laethem
Journals: Journal of Clinical Oncology (10 papers)European Journal of Cancer (4 papers)British Journal of Cancer (3 papers)Clinical Cancer Research (2 papers)Investigational New Drugs (2 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Jan Cosaert

41 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial 2016 · 436 citations

Peers

Countries citing papers authored by Jan Cosaert

Since Specialization

Citations

This map shows the geographic impact of Jan Cosaert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Cosaert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Cosaert more than expected).

Fields of papers citing papers by Jan Cosaert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Cosaert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Cosaert. The network helps show where Jan Cosaert may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jan Cosaert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jan Cosaert Line = papers co-authored together Jan Cosaert links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer British Journal of Cancer ·Neil H. Segal, Jeanne Tie, Scott Kopetz, Michel Ducreux, Eric X. Chen, Rodrigo Dienstmann, Antoine Hollebecque, Matthew J. Reilley, Élena Elez, Jan Cosaert, Jason E. Cain, Blake Stubbins, Nicola Hewson, Zachary A. Cooper, Rakesh Kumar, Josep Tabernero	2024	3
2	1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib Annals of Oncology ·J. De Langen, B.C. Cho, Zofia Piotrowska, Xiao‐Feng Le, Sarah B. Goldberg, 王爱鲜, Isamu Okamoto, Tobias Janik, Raynara Donata dos Santos, K Higuch, Chowalit Nakthong, Jan Cosaert, Mourice Ghosse, Itzhak C Haimovic, Helen Ambrose, Jonathan W. Riess, Helena A. Yu	2022	6
3	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma Oral Oncology ·L. Axe, William N. William, Jennifer Tseng, Shanthi Marur, Dong M. Shin, Barbara A. Murphy, Ezra E.W. Cohen, Christopher Thomas, Maram Srwi Asiri, Jan Cosaert, Nusrat Harun, J. Jack Lee, Ignacio Wistuba, Robert I. Haddad, Bonnie S. Glisson	2018	17
4	Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors Investigational New Drugs ·Patricia LoRusso, Mrinal M. Gounder, Shadia I. Jalal, Valérie André, H L Brantley, Nick Loizos, Jennifer Hall, Timothy R. Holzer, Aejaz Nasir, Jan Cosaert, John Kauh, E. Gabriela Chiorean	2017	16
5	A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Anthony W. Tolcher, Jordan Berlin, Jan Cosaert, John Kauh, Emily Chan, Sarina A. Piha‐Paul, Ronald Harvey, Shande Tang, Kyla Driscoll, Juanfran Serra-Pla, H L Brantley, Ivelina Gueorguieva, David S. Hong	2017	80
6	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC Lung Cancer ·David E. Gerber, Paul Swanson, Ariel López-Chávez, Lucas Wong, Afshin Dowlati, Nathan A. Pennell, Damien M. Cronier, Amy Qin, Robert Ilaria, Jan Cosaert, Ashwin Shahir, Maria Q. Baggstrom	2017	9
7	An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma Clinical Cancer Research ·Danny N. Khalil, Michael A. Postow, Nageatte Ibrahim, Dale L. Ludwig, Jan Cosaert, H L Brantley, Shande Tang, Dmitri Grebennik, John Kauh, Heinz‐Josef Lenz, Keith T. Flaherty, F. Stephen Hodi, Donald P. Lawrence, Jedd D. Wolchok	2016	19
8	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial The Lancet ·William D. Tap, Robin L. Jones, Brian A. Van Tine, Bartosz Chmielowski, Anthony Elias, Douglas Adkins, Mark Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory Pennock, Meera Hameed, Gaurav Shah, Amy Qin, Ashwin Shahir, Damien M. Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K. Schwartz Hit paper breakdown →	2016	436
9	A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Toshihiko Doi, Kohei Shitara, Takashi Kojima, Takayuki Yoshino, Aruna Dontabhaktuni, 智大石, Shande Tang, Jan Cosaert, Atsushi Ohtsu	2016	4
10	An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer Journal of Thoracic Oncology ·Silvia Novello, Giorgio V. Scagliotti, Gilberto de Castro, С.А. Білоковаленко, Rubén Dario Kowalyszyn, Karl-Matthias Deppermann, Edurne Arriola, Lionel Bosquée, Ruslan D. Novosiadly, Tuan S. Nguyen, Amélie Forest, Shande Tang, H L Brantley, Jan Cosaert, Martin Reck	2016	20
11	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy Clinical Cancer Research ·William J. Gradishar, Denise A. Yardley, Rachel M. Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Ruslan D. Novosiadly, Amélie Forest, Tuan S. Nguyen, Jan Cosaert, Dmitri Grebennik, Paul Haluska	2015	54
12	Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors Investigational New Drugs ·Celestia S. Higano, Jordan Berlin, Michael A. Gordon, Patricia LoRusso, Shande Tang, Aruna Dontabhaktuni, Teresa S Corbin, Jan Cosaert, Janice M. Mehnert	2015	14
13	Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers Current Drug Targets ·Eric K. Rowinsky, Jonathan D. Schwartz, Naseem J. Zojwalla, Hagop Youssoufian, Floyd E. Fox, Philippe Pultar, Ruslan Novosyadlyy, Jan Cosaert, Dale L. Ludwig	2011	23
14	Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. Journal of Clinical Oncology ·(unknown), H. A. Burris, Jordi Rodón, A.R. Abdul Razak, Maja J. De Jonge, 小林洪基, Lillian L. Siu, Qinhua Ru, 信太朗河合, David Demanse, Emmanuelle di Tomaso, Jan Cosaert, Cornelia Quadt, José Baselga, Johanna C. Bendell	2011	19
15	Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study Journal of Clinical Oncology ·Chris Verslype, Walter L. Vervenne, Jaafar Bennouna, Yves Humblet, Jan Cosaert, E. Van Cutsem	2009	17
16	Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma Expert Review of Anticancer Therapy ·Bernard Escudier, Jan Cosaert, Pavel Pisa	2008	20
17	Safety of Bevacizumab Treatment in Non–Small-Cell Lung Cancer (NSCLC) Subjects Receiving Full-Dose Anticoagulation (FDAC) Treated on Protocol BO17704 Clinical Lung Cancer ·Jamey Skillings, Are Jay John b. Casicas, Natasha B. Leighl, Jaafar Bennouna, H.‐P. Kuo, Olivia Eguiguren Istuany, Maya Gottfried, McWinner Yawman, José Trigo, Gee‐Chen Chang, Jan Cosaert, C. Manegold	2007	3
18	Platinum drugs in the treatment of non-small-cell lung cancer British Journal of Cancer ·Jan Cosaert, Élisabeth Quoix	2002	85
19	A phase I dose-escalation study of zd0473 combined with paclitaxel in refractory solid malignancies European Journal of Cancer ·U. Gatzemeier, C.J. Twelves, Alan Anthoney, G. Pentheroudakis, G. Groth, Jan Cosaert	2001	5
20	French Multicentre TrialComparing CasodexdC1176,334)Monotherapy with Castration plusNilutamide in Metastatic ProstateCancer: A Preliminary Report European Urology ·C Chatelain, Vanessa Rousseau, Jan Cosaert	1994	19

About Jan Cosaert

Jan Cosaert is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Neurology and Endocrinology, Diabetes and Metabolism, having authored 43 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Research Studies (6 papers), Pancreatic and Hepatic Oncology Research (5 papers), Cancer Genomics and Diagnostics (5 papers), Neuroblastoma Research and Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Microtubule and mitosis dynamics (4 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (336 citations), Pulmonary and Respiratory Medicine (644 citations), Pathology and Forensic Medicine (149 citations) and Hepatology (51 citations). Jan Cosaert has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Jaafar Bennouna, Yves Humblet, Chris Verslype, Walter L. Vervenne, Aijing Shang, Malcolm J. Moore, Eric Van Cutsem, Jean‐Luc Van Laethem, Werner Scheithauer and Sharlene Gill. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, British Journal of Cancer, Clinical Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact